Drug Trial Radar · NCT07729852
Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
7
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Jul 2029
Study completion Jul 2029
Sponsor
- Lead sponsor
- Alterity TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter open-label extension study conducted in France is designed to provide ATH434 orally BID to eligible patients who completed the Phase 2 study ATH434-201, and who may benefit from this treatment according to the evaluation by the Investigator.
Conditions
- Multiple System Atrophy
Interventions
ATH434Drug
ATH434 75 mg tablets administered orally twice daily (BID).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, Severity, and Relationship of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Baseline to completion of study treatment, an average of 1 year.
- Change From Baseline in Clinical Laboratory ParametersTime frame: Baseline to completion of study treatment, an average of 1 year.
- Change From Baseline in Vital SignsTime frame: Baseline to completion of study treatment, an average of 1 year.
- Duration of Exposure to ATH434Time frame: Baseline to completion of study treatment, an average of 1 year.
- Cumulative Dose of ATH434Time frame: Baseline to completion of study treatment, an average of 1 year.
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Hôpital Universitaire Pitié Salpêtrière
Paris, Île-de-France Region, France
Hôpital Pierre-Paul Riquet
Toulouse, Midi-Pyrenees, France
Centre Hospitalier Universitaire de Bordeaux
Bordeaux, New Aquitaine, France
Hôpital de la Timone
Marseille, Provence-Alpes-Côte d'Azur Region, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.